DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 12/24/2018 --DelveInsight has announced the addition of the "Optic Neuritis (ON) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Optic Neuritis for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and forecasted epidemiology of Optic Neuritis from 2018 to 2027 segmented by seven major markets.

Optic Neuritis (ON) as the swelling of the eye's optic nerve. The optic nerve carries light signals from the back of the eye to the brain so that a person can see. A person cannot see clearly if the optic nerve is swollen, damaged or is infected. It is an acute rare disorder which usually occurs in one eye, and is being characterized by the symptoms including blurring of vision, a loss of part or all of central vision, reduced colour vision, and dimness of vision. Most patients with ON have eye pain which is characteristically worsen with the movement of the eye. ON is most common among adults, age 20 to 40 years, and its symptoms generally improve in 80 percent of patients over few weeks. More females are affected than males and approximately five out of every one-hundred thousand people are affected by ON every year.

ON is a rare condition with an estimated annual incidence of 6.4 per 100,000 cases in the United States. Also, the occurrence of ON tends to be the highest in populations located in higher latitudes (in the northern US and Western Europe), and is the lowest in regions closer to the equator. In 15%-20% of people who eventually develop Multiple Sclerosis, Optic Neuritis is their first symptom. The risk of developing Multiple Sclerosis following one episode of ON is approximately 50% within 15 years of any first episode of Optic Neuritis. Various studies have shown that approximately 50% of patients who have ON for the first time will have magnetic resonance imaging (MRI) brain and/or spinal cord abnormalities consistent with MS at the time of the initial ON.

From almost all parts of the world, regions with the highest incidence include northern Europe and middle part of North America. Also, Optic Neuritis is reported to have an incidence of 1-5 cases per 100,000/year; higher the latitude, higher was found to be the incidence of Optic Neuritis.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. Biogen,
2. Mitochon Pharmaceuticals
And many others

Drugs covered

1. Opicinumab (anti-LINGO-1),
2. MP101
And many others

Report Scope

The report covers the descriptive overview of Optic Neuritis explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Optic Neuritis market size covering the drug outreach in 7MM. The report provides the understanding of the future competition in Optic Neuritis by reviewing the market drivers and barriers